Regeneron and Mammoth Biosciences team up on gene editing

EditorNatashya Angelica
Published 25/04/2024, 19:54

TARRYTOWN, N.Y. - Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ:REGN) and Mammoth Biosciences have announced a significant collaboration to develop in vivo CRISPR-based gene editing therapies aimed at treating a variety of diseases by targeting multiple tissues and cell types.

This partnership leverages Regeneron's proprietary adeno-associated viral vectors and Mammoth's ultracompact CRISPR systems to potentially overcome current limitations in gene editing treatment delivery.

Under the agreement, Mammoth will receive a $100 million upfront payment and equity investment from Regeneron. In addition, Mammoth is eligible for up to $370 million per target in milestone payments, plus royalties on future net sales of products resulting from the collaboration. Mammoth also has the option to co-fund and share profits on most programs instead of receiving milestones and royalties.

The collaboration aims to create genetic medicines that can be delivered beyond the liver, expanding the potential treatment reach. Regeneron's delivery technologies include antibody-based targeting that enhances the delivery of genetic medicine payloads to specific tissues and cell types.

Mammoth's contribution lies in their development of novel ultracompact nucleases, which are significantly smaller than the first-generation Cas9 nucleases used in other CRISPR systems.

Christos Kyratsous, Ph.D., Senior Vice President and co-Head of Regeneron Genetic Medicines at Regeneron, emphasized the potential to address multiple diseases and increase the number of patients who could benefit from gene editing treatments. Trevor Martin, Ph.D., co-founder and CEO of Mammoth Biosciences, highlighted the synergy between Mammoth's CRISPR systems and Regeneron's targeted delivery technologies.

Nobel laureate and Mammoth co-founder Jennifer Doudna expressed enthusiasm for the partnership's potential to advance in vivo genetic medicines. The collaboration grants Regeneron access to Mammoth's editing technologies for five and a half years, with an option to extend for two additional years upon payment of a research extension fee.

Regeneron is a biotechnology company that develops and commercializes medicines for various diseases, while Mammoth Biosciences focuses on CRISPR-based therapies. Both companies bring a wealth of scientific expertise to the table in this collaboration, which is based on a press release statement.

InvestingPro Insights

As Regeneron Pharmaceuticals (NASDAQ:REGN) embarks on a promising collaboration with Mammoth Biosciences to revolutionize gene editing therapies, the financial health and market performance of Regeneron provide investors with a comprehensive picture of the company's current standing. Here are some key metrics and insights from InvestingPro that shed light on Regeneron's market position:

Regeneron boasts a robust market capitalization of $97.42 billion, reflecting its significant presence in the biotechnology industry. The company's Price-to-Earnings (P/E) ratio stands at 24.52, with an adjusted P/E ratio for the last twelve months as of Q4 2023 at a slightly lower 22.47, indicating a reasonable valuation relative to earnings.

Despite challenges in the market, Regeneron has maintained a positive revenue growth of 7.76% over the last twelve months, underlining its ability to expand its financial base amidst a dynamic industry landscape.

InvestingPro Tips highlight that Regeneron is not only a prominent player in its field but also demonstrates financial prudence with more cash than debt on its balance sheet, which is a reassuring sign for investors concerned about financial stability.

Moreover, the company's management has been strategically buying back shares, which could be indicative of their confidence in the company's future prospects. For those interested in further insights, there are 10 additional InvestingPro Tips available for Regeneron, offering a deeper dive into the company's financial and operational performance.

For investors seeking more comprehensive analysis and tips on Regeneron, be sure to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro. This exclusive offer provides access to valuable insights that can guide investment decisions in the fast-evolving biotechnology sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.